Search results
Results from the WOW.Com Content Network
St. Jude Medical, Inc. was an American global medical device company headquartered in Little Canada, ... ($46.75 in cash & 0.8708 shares of Abbott common stock, ...
It was not until January 17 that Boston Scientific produced a new offer of $27.2 billion ($80 per share), with the help of Abbott Laboratories. Abbott agreed to purchase $1.4 billion of Boston Scientific stock and pay $4.1 billion for Guidant's vascular intervention business upon completion of the merger.
You wouldn't know that medical device makers Boston Scientific and St. Jude Medical are having a tough time by checking out their stock charts alone. Boston Scientific's hovering near a 52-week ...
Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] 16 2014 Valeant Pharmaceuticals: Allergan, Inc: 49.4 64
For premium support please call: 800-290-4726 more ways to reach us more ways to reach us
Investing isn't easy. Even Warren Buffett counsels that most investors should invest in a low-cost index like the S&P 500. That way, "you'll be buying into a wonderful industry, which in effect is ...
Robert B. Ford is an American businessman and the thirteenth chief executive officer at Abbott Laboratories, a publicly-traded medical devices and health care company based in Abbott Park, Illinois. [1] He received a bachelor's degree from Boston College and an MBA from Haas School of Business. [2]
Other M&A assignments include advising DuPont on its $68 billion merger of equals with The Dow Chemical Company to create DowDuPont; [17] Medivation on its sale to Pfizer Inc., and Abbott Laboratories on its $31 billion acquisition of St. Jude Medical in the two largest Healthcare transactions of 2016. [18]